Lyxumia, Sanofi’s newly approved Type 2 diabetes drug could become a blockbuster, although it is the fourth drug in its class to come to market, insists David Solomon, CEO of Zealand Pharma AS, which discovered the drug and licensed it in 2003 to a company that Sanofi later acquired.
The competition isn’t a hurdle because the market for glucagon-like peptide 1 agonists, the class of drugs including Lyxumia (lixisenatide), is growing so rapidly even a small share of it...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?